Business
CYCLE: Losses increased as sales fell to zero, but a key patent and scaling projects mark strategic progress
CYCLE: Losses increased as sales fell to zero, but a key patent and scaling projects mark strategic progress
About this update from Cyclezyme Ab
Net sales dropped to zero and losses widened in Q1 2026 as investments in technology and patents continued. A key European patent was granted, and major development projects with partners are advancing, positioning the company for future commercialization.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.